Prostate Cancer Chemoprevention using a Natural Agent
Prostate Cancer Chemoprevention using a Natural Agent
批准号:
8445062
负责人:
Shailesh Singh
金额:
$18.47万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-04-01 至 2015-03-31
关键词:
AdoptedAndrographisAnimalsAntibodiesApplications GrantsB-LymphocytesBiological AssayC57BL/6 MouseCancer PatientCell CountCell ProliferationCell SurvivalCell physiologyCell-Mediated CytolysisCellsChemopreventionChemopreventive AgentColorCytolysisCytoplasmic GranulesDataDendritic CellsDevelopmentDiseaseEffectivenessEnzyme-Linked Immunosorbent AssayFlow CytometryGrowthHost DefenseImageImmuneImmune responseImmune systemImmunohistochemistryImmunologic SurveillanceIn VitroIncidenceLuciferasesMalignant NeoplasmsMalignant neoplasm of prostateMature T-LymphocyteModelingMolecularMusNK Cell ActivationNatural Killer CellsNeoplasm MetastasisNeoplastic Cell TransformationOral AdministrationPTEN genePatientsPhenotypePreventionProductionProstatic NeoplasmsRecruitment ActivityRoleSerine ProteaseSerumSiteSystemT cell responseT-LymphocyteTestingToxic effectTranslatingTumor ImmunityTumor-Infiltrating Lymphocytesandrographolidebasebioluminescence imagingcancer cellcancer chemopreventionclinical applicationclinically relevantcytokinecytotoxicgranulysinin vivoinnovationinsightkillingslymphoblastmalemonocytemouse modelneoplastic cellnovelperforinprostate cancer cellprostate cancer modelprostate cancer preventionpublic health relevanceresearch studyrestorationtreatment strategytumortumor growthtumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The long latency of prostate cancer (PCa) provides a window of opportunity for chemoprevention strategies. Most such strategies are focused on controling and/or reversing the mechanisms involved in neoplastic transformation and cancer progression. It is well accepted that, during development and progression, tumor cells evade the patient's defense system. In this regard, natural killer (NK) cells are cellular effectors of the innate immune system and are required for activation of the host defense system and for destruction of tumor cells. In PCa patients, however, the function of NK cells and their numbers are often compromised and/or depleted. Therefore, enhancing the function of NK cells by immunomodulatory compounds is a promising approach for PCa prevention. Recently, we demonstrated the immunomodulatory effects of andrographolide (AG), a natural compound isolated from Andrographis paniculata (AP), on NK cells and have established its antitumor effects in mice bearing PCa PTEN syngeneic tumors. Our preliminary results provide a rationale to investigate the function of AG in potentiating NK cells, which can act to eliminate PCa cells. Based on these encouraging preliminary data, we hypothesize that AG inhibits PCa growth by potentiating the anti-tumor activity of NK cells, thus offering an innovative, immune-based chemopreventive strategy for PCa. To test this hypothesis, we propose two specific aims. The first aim will use mouse models to determine the potential of AG in boosting NK cell activity against PCa. This will be achieved by establishing an interrelationship between the in vivo effects of AG through NK cel mobilization and cytotoxic activities and the effectiveness of AG in adaptive T cell responses through modulation of cytokine production by NK cells. In the second aim, we will establish the effects of AG on development, proliferation/survival, and cytotoxic function of NK cells. These studies, which will determine the effectiveness of AG in PCa chemoprevention achieved through boosting NK cell function, make the proposal clinically relevant and highly translational.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Anti-CCL25 mAb to treat castration resistant prostate cancer
-
批准号:9264953
-
项目类别:
-
资助金额:$35.0万
-
财政年份:2017
-
负责人:Shailesh Singh
-
依托单位:
Anti-CXCL13 mAb to mitigate prostate cancer health disparities
-
批准号:8998175
-
项目类别:
-
资助金额:$31.53万
-
财政年份:2015
-
负责人:Shailesh Singh
-
依托单位:
Role of chemokine receptor in disparities associated with prostate cancer progres
-
批准号:8918551
-
项目类别:
-
资助金额:$18.39万
-
财政年份:2013
-
负责人:Shailesh Singh
-
依托单位:
Role of chemokine receptor in disparities associated with prostate cancer progres
-
批准号:9340094
-
项目类别:
-
资助金额:$9.58万
-
财政年份:2013
-
负责人:Shailesh Singh
-
依托单位:
Role of chemokine receptor in disparities associated with prostate cancer progres
-
批准号:9137633
-
项目类别:
-
资助金额:$12.42万
-
财政年份:2013
-
负责人:Shailesh Singh
-
依托单位:
Role of chemokine receptor in disparities associated with prostate cancer progres
-
批准号:8585726
-
项目类别:
-
资助金额:$21.23万
-
财政年份:2013
-
负责人:Shailesh Singh
-
依托单位:
Role of CCL25-CCR9 in Prostate Cancer
-
批准号:8638910
-
项目类别:
-
资助金额:$35.38万
-
财政年份:2013
-
负责人:Shailesh Singh
-
依托单位:
Role of CCL25-CCR9 in Prostate Cancer
-
批准号:8414694
-
项目类别:
-
资助金额:$35.38万
-
财政年份:2013
-
负责人:Shailesh Singh
-
依托单位:
Role of chemokine receptor in disparities associated with prostate cancer progres
-
批准号:8728793
-
项目类别:
-
资助金额:$20.59万
-
财政年份:2013
-
负责人:Shailesh Singh
-
依托单位:
Research Education Core
-
批准号:10693359
-
项目类别:
-
资助金额:$22.22万
-
财政年份:2005
-
负责人:Shailesh Singh
-
依托单位:
Research Education Core
-
批准号:10007640
-
项目类别:
-
资助金额:$14.75万
-
财政年份:2005
-
负责人:Shailesh Singh
-
依托单位:
Research Education Core
-
批准号:10327915
-
项目类别:
-
资助金额:$22.67万
-
财政年份:2005
-
负责人:Shailesh Singh
-
依托单位:
Research Education Core
-
批准号:9368967
-
项目类别:
-
资助金额:$27.48万
-
财政年份:--
-
负责人:Shailesh Singh
-
依托单位:
海外基金